Recombinant Human Platelet Basic Protein (PPBP), Active

Beta LifeScience SKU/CAT #: BLC-05529P

Recombinant Human Platelet Basic Protein (PPBP), Active

Beta LifeScience SKU/CAT #: BLC-05529P
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description Recombinant Human Platelet Basic Protein (PPBP), Active is produced by our E.coli expression system. This is a protein fragment.
Purity Greater than 97% as determined by SDS-PAGE and HPLC.
Endotoxin Less than 1.0 EU/μg as determined by LAL method.
Activity Fully biologically active when compared to standard. The biological activity determined by a chemotaxis bioassay using human peripheral blood neutrophils is in a concentration range of 1.0-10.0 ng/ml.
Uniprotkb P02775
Target Symbol PPBP
Synonyms B TG1; Beta TG ; Beta thromboglobulin; Beta-TG; C-X-C motif chemokine 7; Chemokine (C X C motif) ligand 7; Connective tissue activating peptide III; CTAP 3; CTAP III; CTAP-III; CTAP-III(1-81); CTAP3; CTAPIII; CXC chemokine ligand 7; CXCL 7; CXCL7; CXCL7_HUMAN; LA PF 4; LA-PF4; LDGF; Leukocyte derived growth factor; Leukocyte-derived growth factor; Low-affinity platelet factor IV; Macrophage-derived growth factor; MDGF; NAP 2; NAP-2; NAP-2(1-63); NAP-2(1-66); NAP-2(73); NAP-2(74); Neutrophil activating peptide 2; Neutrophil-activating peptide 2(1-63); PBP; Platelet basic protein; PPBP; Pro platelet basic protein (chemokine (C-X-C motif) ligand 7); Pro platelet basic protein; SCYB7; Small inducible cytokine subfamily B member 7; Small-inducible cytokine B7; TC1; TC2; TGB; TGB1; THBGB; THBGB1; Thrombocidin 1; Thrombocidin 2; Thromboglobulin; beta-1
Species Homo sapiens (Human)
Expression System E.Coli
Tag Tag-Free
Complete Sequence AELRCMCIKT TSGIHPKNIQ SLEVIGKGTH CNQVEVIATL KDGRKICLDP DAPRIKKIVQ KKLAGDESAD
Expression Range 59-128aa
Protein Length Partial
Mol. Weight 7.6 kDa
Research Area Immunology
Form Liquid or Lyophilized powder
Buffer 0.2 µm filtered 20 mM PB, pH 7.4, 50 mM NaCl, lyophilized
Storage 1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.

Target Details

Target Function LA-PF4 stimulates DNA synthesis, mitosis, glycolysis, intracellular cAMP accumulation, prostaglandin E2 secretion, and synthesis of hyaluronic acid and sulfated glycosaminoglycan. It also stimulates the formation and secretion of plasminogen activator by human synovial cells. NAP-2 is a ligand for CXCR1 and CXCR2, and NAP-2, NAP-2(73), NAP-2(74), NAP-2(1-66), and most potent NAP-2(1-63) are chemoattractants and activators for neutrophils. TC-1 and TC-2 are antibacterial proteins, in vitro released from activated platelet alpha-granules. CTAP-III(1-81) is more potent than CTAP-III desensitize chemokine-induced neutrophil activation.
Subcellular Location Secreted.
Protein Families Intercrine alpha (chemokine CxC) family
Database References

Gene Functions References

  1. Low CXCL7 expression is associated with posterior longitudinal ligament ossification. PMID: 29782494
  2. In the prospective population-based Atherosclerosis Risk in Communities cohort, beta-thromboglobulin was not associated with cardiovascular disease risk. PMID: 28531882
  3. Cleavage of a factor Xa-specific chromogenic substrate was observed when Beta-TG was incubated with factor X, suggesting a direct interaction between Beta-TG and factor X. Beta-TG modulate coagulation in vitro via an interaction with factor X. PMID: 28384443
  4. This study demonstrated that platelet basic protein was detected in the serums of Alzheimer disease patients PMID: 27911324
  5. DEFA1, DEFA3, and PPBP expression was significantly increased in hyperlipidemia and coronary heart disease patients compared with controls. PMID: 28420383
  6. These results suggest that aberrant CXCL7 expression in peripheral blood cells is induced by renal cell carcinoma cells and may serve as a novel biomarker in the diagnosis of renal cell carcinoma . PMID: 28985012
  7. Two haplotype blocks, one upstream to the coding region of UGT2A1 (rs146712414, P = 9.1 x 10(-5); odds ratio [OR], 1.34; 95% confidence interval [CI], 1.16-1.56) and one downstream of the genes PF4/PPBP/CXCL5 (rs1595009, P = 1.3 x 10(-4); OR, 1.32; 95% CI, 1.15-1.52), were associated with AgP. PMID: 28467728
  8. NMR and modeling studies indicated that glycosaminoglycans (GAG) heparin binding to the heterodimer is distinctly different from the CXC chemokine ligand 7 (CXCL7) monomer. PMID: 28368308
  9. Cby's C-terminal domain alone binds to TC-1 with significantly greater affinity compared to full-length Cby, implying that target binding of the coiled-coil domain is affected by the flanking disordered regions. PMID: 27082063
  10. CXCL7 plays a promoting role in regulating the growth and metastasis of cholangiocarcinoma. PMID: 27959418
  11. Data suggest that neutrophil-activating peptide 2 (NAP-2) secreted by NK cells can bind to CXC Chemokine Receptor 2 (CXCR2) on mesenchymal stem cells (MSCs) leading to stimulation of its recruitment. PMID: 27052313
  12. Utilizing mass spectrometry-based proteomics, platelet basic protein has been identified as a candidate serum biomarker for transient ischemic attack PMID: 26307429
  13. Synovial Cxcl7 mRNA and protein were increased in early rheumatoid arthritis compared to uninflamed controls and resolving arthritis. PMID: 25858640
  14. Studied and characterized the dynamics and thermodynamic stability of monomer and homodimer structures of CXCL7. PMID: 26297927
  15. Leptin and neutrophil-activating peptide act synergistically to promote mesenchymal stem cell senescence through enhancement of the PI3K/Akt signaling pathway in systemic lupus erythematosus patients. PMID: 25989537
  16. CXCL7/CXCR2 signalling pathways are a predictive factor of poor outcome in metastatic colon cancer. PMID: 25580640
  17. CXCR4-CXCL12-CXCR7 regulates mTOR signaling in renal cancer cells. PMID: 24991762
  18. The antimicrobial thrombocidin peptides are found in human blood platelets, are deletion products of CXC chemokines and have antibacterial and antifungal activity. PMID: 10877842
  19. The level of beta-thromboglobulin was found significantly higher in female patients with rheumatoid arthritis. PMID: 23052484
  20. Testing of bacterial resistance to platelet antimicrobial lmw proteins (PMPs) may be advisable as a predictive indicator of susceptibility to treatment of infections such as infective endocarditis and other local infections of biofilm nature. PMID: 23619231
  21. beta-TG was evaluated for familial mediterranean fever cases and healthy controls, beta-TG levels were found significantly lower among patients; it is hypothesized that this difference may have resulted from the effect of colchicine use on platelet functions. PMID: 22939812
  22. Examined the prognostic values of SARS-associated proteome, and deciphered the identities of those with prognostic values.The associations of decreased serum PF4 and increased serum beta-TG levels with poor prognosis were confirmed by Western blot. PMID: 22740477
  23. modulates antimicrobial activity of phagocytes against L. pneumophila PMID: 22101183
  24. positive ratios of CXCR7, CXCL12 and CXCL11 in oral leukoplakia and oral squamous cell carcinoma tissues respectively, were significantly higher than that in normal epithelia PMID: 21442287
  25. Using microdialysis techniques we detected beta-TG release during an inflammatory response. We conclude that local platelet activation is induced by the heating stimulus. PMID: 20510637
  26. beta-TG is cleaved after being released from activated platelets, thereby becoming less mitogenic for fibroblasts PMID: 20224257
  27. CXCL7 promotes neutrophil adhesion to vascular endothelium and induces transendothelial migration. PMID: 12193731
  28. one or more high molecular weight protein is released from alpha-granules and is broken down into smaller fragments after release to form beta-thromboglobulin (beta-TG)-like proteins by the action of metal dependent proteases. PMID: 12297130
  29. Gene profiling iodentified PPBP from peripheral blood cells in coronary artery disease. PMID: 12878486
  30. Platelet basic protein is downregulated by glucocorticoids, and is defined as an immunosuppressive target of glucocorticoids. PMID: 14673015
  31. Our observations indicate that PBP and its derivates are constituents of the antimicrobial arsenal of human monocytes. Their increased expression after exposure to microorganisms allows a rapid host response to pathogens. PMID: 15316029
  32. activated human skin mast cells (MCs) convert CTAP-III into biologically active NAP-2 through proteolytic cleavage by released chymase. PMID: 16317101
  33. stromal-stimulated monocytes can serve as an additional source for CXCL7 peptides in the microenvironment and may contribute to the local regulation of megakaryocytopoiesis PMID: 16391012
  34. levels of BDNF and beta-TG in blood of Alzheimers patients is decreased; BDNF and beta-TG are associated with degree of platelet activation PMID: 16807663
  35. NAP-2 has the potential to induce inflammatory responses within the atherosclerotic plaque. By its ability to promote leukocyte and endothelial cell activation, such a NAP-2-driven inflammation could promote plaque rupture and acute coronary syndromes. PMID: 17045893
  36. CXCL7 decreased serum levels in advanced MDS, suggesting the possibility of a concerted disturbance of transcription or translation of these chemokines in advanced MDS PMID: 17220270
  37. delayed pressure urticaria may be associated with increased secretion of platelet chemokines PF4 and beta-TG, similar to that observed in cold urticaria PMID: 18632422
  38. stimulates the migration of mesenchymal stem cells in vitro PMID: 18707017

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed